netFormulary NHS
Bedfordshire and Luton Joint Formulary
Bedford Hospital NHS Trust
Bedfordshire CCG
Luton & Dunstable University Hospital NHS Foundation Trust
Luton CCG
 Search
 Formulary Chapter 11: Eye - Full Chapter
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

 Details...
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept 40mg/1mL (Eylea®)
(Intravitreal Injection )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. Funded by NHS England.

Restricted - prescribing by consultant Ophthalmologists in-line with NICE TA's below.
 
Link  INTRAVITREAL INJECTIONS USED IN OPHTHALMOLOGY ALGORITHM
Link  NICE TA294: Macular degeneration (wet age-related) - aflibercept
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
   
Bevacizumab intravitreal 1.25mg in 0.05mL (Avastin®)
(Injection)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red

Approved for the treatment of retinopathy of prematurity.

 
   
Ranibizumab 0.5mg/0.5mL (Lucentis®)
(Intravitreal Injection )
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted - prescribing by consultant Ophthalmologists:

1. For the treatment of age related macular degeneration in accordance with NICE TA155.
2. For treating diabetic macular oedema in accordance with NICE TA274.

3. For Central Retinal Vein Occlusion in accordance with NICE TA283

4. For treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia in accordance with NICE TA 298.


 
Link  INTRAVITREAL INJECTIONS USED IN OPHTHALMOLOGY ALGORITHM
Link  NICE TA155: Macular degeneration (age-related) ranibizumab
Link  NICE TA274: Macular oedema (diabetic) - ranibizumab
Link  NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Link  NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
   
Verteporfin (Visudyne®)
(Intravenous infusion)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

JPC Recommendations:
 To support the use of PDT with verteporfin for the treatment of Chronic Central Serous Retinopathy.
 Approval is subject to patient outcomes being provided (via Blueteq reauthorisation process).
 
Link  JPC Bulletin 254: Photodynamic therapy (PDT) with verteporfin (Visudyne®) for chronic central serous retinopathy
   
11.08.02  Expand sub section  Vitreomacular traction to top
 ....
 Non Formulary Items
Pegaptanib Sodium  (Macugen®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Not recommended by NICE.
Link  NICE TA155: guidance on pegaptanib in AMD (August 2008)
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment  

Amber

Amber medicines are considered suitable for GP prescribing following specialist initiation.  

Green

These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations   

Amber SCG

Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.   

Black

A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. Do not prescribe.   

netFormulary